Device Trial Radar · NCT02359617
Continuous Glucose Sensing at the Site of Subcutaneous Insulin Administration
Last checked: Nov 20, 2026Latest source record: Apr 27, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Feb 2013
Primary completion
Oct 2014
Study completion Mar 2015
Sponsor
- Lead sponsor
- Medical University of GrazAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- European Commission
- First posted
- Feb 10, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study seeks to evaluate a novel treatment approach for performing continuous real-time glucose sensing and insulin delivery at the same subcutaneous tissue site.
Conditions
- Type 1 Diabetes
Interventions
insulin deliveryDrug
Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.
glucose sensingDevice
Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean absolute relative difference between sensor readings and capillary glucose readingsTime frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of Graz
Graz, Styria, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.